The global pharmaceutical sector operates under a highly advanced and ever-evolving regulatory environment. With the emergence of new therapeutic modalities based on biologics, cell and gene therapies, and even artificial intelligence diagnostics, the role of national/regional regulators has transcended its Read More …
Tag: QA
Risk Management is a “Living, Breathing” Obligation, FDA Official Warns
Baltimore – The main problem for medical device makers cited for regulatory issues is risk management. According to the keynote address presented by Keisha Thomas at the RAPS Quality Conference, where Ms. Thomas is currently Associate Director for Compliance and Read More …
The V-Model in Computer Systems Validation: Structural Mechanics, Differences, and Evolving into Computer Software Assurance
Computer Systems Validation (CSV) acts as the main regulatory control framework for guaranteeing that computerized systems utilized within GxP-regulated life science industries such as the pharmaceutical, biotech, and medical device industries function in a consistent, reliable manner that fully complies Read More …
A Comprehensive Guide to Data Integrity, GxP Compliance, and Audit Readiness
1. The Regulatory Landscape and Compliance Imperatives Operating an Enterprise Resource Planning (ERP) platform within a GxP-regulated life sciences organization carries exceptionally high stakes, as any error in a batch record or quality process can directly compromise patient safety and Read More …
A Comprehensive Analysis of ICH Q9(R1) and the Evolving Standards of Quality Risk Management
The formal adoption of the ICH Q9(R1) guideline in January 2023 represents a pivotal advancement in the global harmonization of pharmaceutical quality standards, addressing nearly two decades of implementation experience and evolving industrial complexities. Originally introduced in 2005, the ICH Read More …
The Strategic Transition to Quality 4.0: Integrating Digital Intelligence into Organizational Excellence
The global industrial landscape is presently navigating a foundational transformation, shifting from traditional quality management paradigms to a digitized, interconnected framework known as Quality 4.0. This evolution represents the alignment of quality management practices with the technological advancements of the Read More …
The Definitive Guide to CAPA Management: Remediating Ineffective Systems and Preventing Repeat Deviations
Executive Summary In the global pharmaceutical landscape of 2026, the Corrective and Preventive Action (CAPA) system is no longer viewed as a mere documentation exercise. It is the engine of continuous improvement. This guide explores why the WHO often cites Read More …
Modern Laboratory Data Integrity: LIMS, ALCOA+, and Preventing “Testing into Compliance”
The contemporary industrial landscape, particularly within the pharmaceutical and high-precision textile sectors, is currently undergoing a radical transformation driven by the convergence of stringent regulatory oversight and the urgent necessity for sustainable technological innovation. At the heart of this evolution Read More …
Explore the most common pharmaceutical deviations in Bangladesh
Explore the most common pharmaceutical deviations in Bangladesh: Learn expert Root Cause Analysis (RCA) techniques and CAPA strategies for DGDA & GMP compliance The pharmaceutical landscape in Bangladesh has evolved from a local manufacturing hub to a sophisticated global exporter. Read More …
10 Must-Follow Change Control Rules in Pharmaceutical Manufacturing
1. No Change Without Formal Approval In pharmaceutical manufacturing, no change—whether related to process, material, equipment, or documentation—should be implemented without prior approval through a formal Change Control system. Regulatory authorities like Directorate General of Drug Administration and US Food Read More …